Relafen 750, or novel formulation of naproxen, presents the compelling case from the biochemical pharmacy standpoint. This mechanism of action, mainly involving suppression of cyclooxygenase enzymes and COX-1 and COX-2 – contributes to significant lowering in prostaglandin production. Within our biochemical context, the drug's potency is closely